본문 바로가기

바이오스펙테이터

기사본문

PH Pharma develops a New Drug by Introducing New Materials from Germany and Belgium

입력 2018-11-09 10:17 수정 2018-11-09 10:17

바이오스펙테이터 Jongwon jang 기자

Materials Imported from the World → Development in a Short Period of Time → Strategic Technology Transfer ... Completed the 2b-phase clinical trial for glaucoma - 1b-phase clinical trial for non-alcoh

▲피에이치파마 허호영(왼쪽)·김재식 대표.

PH Pharma is a domestic company that is currently developing new drugs. It was founded in 2015 by President Heo Ho-yeong, who had been working to develop new drugs for global markets. President Heo Ho-yeong was deeply involved in 10 major M&As and IPOs, including the M&A of BiPar Science and Sanofi, and the IPOs of CytomX, Geron, and Nektar Therapeutics.

In the fourth year since its startup, PH Pharma is now consolidating its business strategy, which consists of the introduction of prospective candidate materials for new drugs from global companies, development of new drugs thereof in a short period of time, and transference of the technologies of new drugs to other companies. The company has completed the 2b phase clinical trial for the therapeutics for glaucoma, the ‘PHP-201’; and currently has the 1b-phase clinical trial in the U.S.A. in progress for the therapeutics for non-alcoholic steatohepatitis. The two materials, put into the development of new drugs, were imported from Germany (Bayer) and Belgium (Amakem), respectively.

PH Pharma appointed Kim Jae-sik as the Chief Financial and Chief Executive Officer, who was previously a Head of Business Administration and the Planning Division of Daewoong Pharmaceutical Co., Ltd., and Chief Financial Officer of Hanmi Science Co., Ltd. President Kim introduced the company with, “... PH Pharma is characterized by the strongest pipeline platform technology, and the people therein.”

① PHP-201: Rhokinase Suppression Mechanism, Suppression of Glaucoma by Relaxation of the Outlet of Aqueous Humor

PHP-201 is a Rhokinase inhibitor that has recently been spotlighted as a new mechanism of therapeutics for glaucoma. PHP-201 inhibits Rhokinase, and thereby reduces the contraction of smooth muscle and intraocular pressure.

PH Pharma imported the material from Amakem in Belgium, completed 2-phase clinical trials in the U.S.A. and Europe, and conducted 1b-phase and 2b-phase clinical trials in Korea and Japan. The new drug will target the Asian market, since it has shown excellent therapeutic effects for the glaucoma under normal intraocular pressure frequently observed in Eastern Asian people.

The company stated, “... 2b-phase clinical trials have been completed; 10 medical institutions, including Seoul National University Hospital and Seoul St. Mary’s Hospital of the Catholic University, participated with 120 subjects, and now the results are being analyzed. We are preparing for the 3-phase clinical trials to be held in China and Japan.” The 3-Phase clinical trials are planned to be carried out with 600 subjects.

② PHP-303: Aiming for Big Market ‘NASH’, the applicability can be extended to the fields of rare diseases

PH Pharma has also started to develop the therapeutics targeted at non-alcoholic steatohepatitis, for which therapeutic agents are currently unavailable. PH-303, imported from Bayer, Germany, is the material put into the development of the new therapeutics.

The company explained, “... PH-303 is a drug that inhibits neutrophil elastase; compared with other materials being developed by competitors, it is characterized by manifesting a specific working mechanism.” PHP-303 inhibits neutrophil elastase, and thereby suppresses inflammatory immuno-reactions; it also improves insulin resistance.

Kim stated, “... PH-303 enables anti-inflammatory action, as well as the improvement of insulin resistance; therefore it is expected to reveal its efficacy at the initial and middle stages of NASH. The 1b-phase clinical trial currently being conducted in the U.S.A. will be completed in the first half of next year.”

PH Pharma is also developing the new Toxin, which is used for the ‘Antibody-Drug Conjugates (ADC)’ through its subsidiary company, PH Oncology. President Kim said, “... We have concluded that there are many unmet demands associated with the Toxin as an element comprising the ADC; therefore we have prepared the platform technology for the development of Toxin.”

Kim also emphasized, “... prominent researchers, including President Heo Ho-yeong, who have managed R&Ds in the global pharmaceutical companies, are now entrained on our track of PH Pharma. The competencies of these researchers, including their networked resources, will be exploited according to the strategy of PH Pharma, which aims for the quick and successful development of global new drugs, and the resulting technology transference through the right imported materials.”

카카오스토리로 기사 공유하기